Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds. Amidst market turbulence, companies will continue their search for mid-sized pipeline-centric growth assets, given increasing cash balances and uncertain revenue projections. Will M&A continue to remain an appetizing strategic policy to fuel further consolidation?
Analysis structure
Explore and visualize M&A dynamics in the pharmaceutical and biotechnology industries:
- executive summary
- trend analysis
- major deal discussion
- looking ahead
- potential targets
Key questions answered
- Explore and assess recent deals based on deal size and company type
- How is the industry using M&A as a vehicle to propel a strategy for growth?
- Delve deeper into the largest deals of 2015
- What’s the outlook for M&A in 2016?
- What companies are still out on the prowl for M&A deals?
- What companies constitute the most likely targets?
Highlights
- $437bn worth of deals has been completed in 2015 for pharmaceutical and biotechnology companies.
- Biggest deal: Pfizer’s $160bn deal for Allergan will becomes the biggest deal in the industry’s history
- Biggest spenders: Companies in Datamonitor Healthcare’s PharmaVitae portfolio were involved in $385bn worth of deals
- Portfolio transformation: Companies continue to explore asset stripping
- Targeted deal-making: Companies continue to gain a larger foothold in therapeutic areas of strength
- Tax-inversions: Tax-inversions have spilt over in 2015
- 2016 Outlook: Pipeline-centric acquisitions will continue to bolster companies that have remained largely passive